{"doi":"10.1001/jamanetworkopen.2021.4203","title":"USPSTF Recommendation Statement on Hypertension Screening in Adults—Where Do We Go From Here?","abstract":"Compared with other modifiable risk factors, hypertension is associated with more target end-organ damage, cardiovascular disease (CVD) events, and disability-adjusted life-years lost in the United States. Out-of-office BP monitoring is also recommended for diagnostic confirmation before starting treatment. The USPSTF considered this recommendation to be a grade A, indicating there is high certainty that the net benefit of screening for hypertension is substantial. e recommendation from the 2021 USPSTF recommendation statement 4 was based on evidence from a systematic review by Guirguis-Blake et al 5 commissioned by the USPSTF to evaluate key questions related to the benefits and harms of screening for hypertension in adults, the accuracy of office BP measurement for initial screening, and the accuracy of various confirmatory BP measurement methods after an initial high office BP. Regarding benefits of hypertension screening, the systematic review by Guirguis-Blake et al 5 identified 1 good-quality community-based randomized clinical trial conducted in Canada examining the effectiveness of a 10-week multicomponent CVD health promotion program intervention with hypertension screening as a primary component on CVD outcomes (ie, the change in mean annual rate of hospital admissions for acute myocardial infarction, heart failure, or stroke in the year before compared with the year after intervention implementation) among residents 65 years or older. BP was measured by trained volunteers using a validated device. Compared with no intervention, the intervention led to a 9% reduction in hospitalizations per 1000 CVD events. The systematic review by Guirguis-Blake et al 5 also identified a few studies on the harms of hypertension screening. Data from these studies suggested minimal associations of hypertension screening with quality of life and psychological outcomes.","journal":"JAMA Network Open","year":2021,"id":196483,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":6,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9523,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2021-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":531912,"name":"Corey Bradley","orcid":"0000-0002-3988-1023","position":1,"is_corresponding":false},{"id":281843,"name":"Daichi Shimbo","orcid":"0000-0001-6302-8834","position":2,"is_corresponding":false},{"id":106974,"name":"D. Edmund Anstey","orcid":"0000-0001-9330-1563","position":0,"is_corresponding":true}],"reference_count":14,"raw_metadata":null,"created_at":"2026-07-18T23:50:15.704473Z","pmid":"33904916","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}